Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

Autor: Ana Bosch, Mikkel G. Terp, Henrik J. Ditzel, Monique F. Hundebøl, Neil Portman, Lene E. Johansen, Kamila Kaminska, Gabriella Honeth, Carla Maria Lourenco Alves, Martin Bak, Odd L. Gammelgaard, Elgene Lim, Martina Tuttolomondo, Sidse Ehmsen

Publikováno v: Nature Communications
Alves, C L, Ehmsen, S, Terp, M G, Portman, N, Tuttolomondo, M, Gammelgaard, O L, Hundebøl, M F, Kaminska, K, Johansen, L E, Bak, M, Honeth, G, Bosch, A, Lim, E & Ditzel, H J 2021, ' Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer ', Nature Communications, vol. 12, 5112 . https://doi.org/10.1038/s41467-021-25422-9
Nature Communications, Vol 12, Iss 1, Pp 1-15 (2021)

CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy have shown impressive efficacy in estrogen receptor-positive advanced breast cancer. However, most patients will eventually experience disease progression on this combination, underscoring t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::909c54d06c561d241308a49e7f7f6e84
https://pubmed.ncbi.nlm.nih.gov/34531405

Emerging patient-specific treatment modalities in head and neck cancer - a systematic review

Autor: Elicin, O., Cihoric, N., Vlaskou Badra, E., Ozsahin, M.

Publikováno v: Expert opinion on investigational drugs, vol. 28, no. 4, pp. 365-376

Head and neck cancer (HNC) is an immunosuppressive disease that demonstrates heterogeneous molecular characteristics and features of tumor-host interaction. Beside radiotherapy and surgery, the current standard of care in systemic treatment involves

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1900::e2008e79282ca908c3f45cd3c1d13431
https://serval.unil.ch/resource/serval:BIB_2709C035C3A9.P001/REF.pdf

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

Autor: Loriot, Yohann, Necchi, Andrea, Park, Se Hoon, Garcia-Donas, Jesus, Huddart, Robert, Burgess, Earle, Fleming, Mark, Rezazadeh, Arash, Mellado, Begoña, Varlamov, Sergey, Joshi, Monika, Duran, Ignacio, Tagawa, Scott, Zakharia, Yousef, Zhong, Bob, Stuyckens, Kim, Santiago-Walker, Ademi, De Porre, Peter, O’Hagan, Anne, Avadhani, Anjali, Siefker-Radtke, Arlene, Houédé, Nadine

Publikováno v: New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2019, 381 (4), pp.338-348. ⟨10.1056/NEJMoa1817323⟩

Alterations in the gene encoding fibroblast growth factor receptor (In this open-label, phase 2 study, we enrolled patients who had locally advanced and unresectable or metastatic urothelial carcinoma with prespecifiedA total of 99 patients in the se

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffcfc170e758d7ea02e09dd18fd05524

Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia

Autor: Chalandon, Yves, Thomas, Xavier, Hayette, Sandrine, Cayuela, Jean-Michel, Abbal, Claire, Huguet, Françoise, Raffoux, Emmanuel, Leguay, Thibaut, Rousselot, Philippe, Lepretre, Stéphane, Escoffre-Barbe, Martine, Maury, Sébastien, Berthon, Céline, Tavernier, Emmanuelle, Lambert, Jean-François, Lafage-Pochitaloff, Marina, Lhéritier, Véronique, Chevret, Sylvie, Ifrah, Norbert, Dombret, Hervé, Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)

Publikováno v: Blood, Vol. 125, No 24 (2015) pp. 3711-3719

In this study, we randomly compared high doses of the tyrosine kinase inhibitor imatinib combined with reduced-intensity chemotherapy (arm A) to standard imatinib/hyperCVAD (cyclophosphamide/vincristine/doxorubicin/dexamethasone) therapy (arm B) in 2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76ff7b8fa7c747ce8aaa642d7f259a20
https://doi.org/10.1182/blood-2015-02-627935

Nanocrystals of a potent p38 MAPK inhibitor embedded in microparticles: Therapeutic effects in inflammatory and mechanistic murine models of osteoarthritis

Autor: François Pfefferlé, Eric Allémann, Olivier Jordan, Christian Alexander Seemayer, Pierre Marc Xavier Maudens

Publikováno v: Journal of Controlled Release, Vol. 276 (2018) pp. 102-112

This study aimed to formulate nanocrystal-polymer particles (NPPs) containing the potent p38α/β MAPK inhibitor PH-797804 (PH-NPPs) and to test their extended-release properties over months in comparison to those of conventional PH microparticles fo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd923cfc3df1e7e5e0b9a10c1e9b7bbf
https://pubmed.ncbi.nlm.nih.gov/29524442